X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to X4 Pharmaceuticals (XFOR) Reports Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals (XFOR) PT Lowered to $4 at Stifel

November 13, 2024 4:00 PM EST

Stifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $4.00 (from $5.00) while maintaining a Buy rating.

The analyst comments "The XOLREMDI launch in WHIM syndrome was always going to be a show-me story for investors and the longer-term opportunity... More